Jane Grogan, Head of Research at Biogen Inc., filed a Form 4 on November 2, 2026, disclosing the vesting and partial tax-withholding disposition of restricted stock units transacted on October 30, 2026.

Key Highlights

  • RSU conversion: 695 restricted stock units were converted to common stock on October 30, 2026, at a price of $0, reported as an acquisition (transaction code M).
  • Tax-withholding disposition: 345 shares were disposed of on October 30, 2026, at a price of $253.62 per share (transaction code F).
  • Resulting ownership: Following both transactions, Grogan directly held 4,408 shares of Biogen common stock, according to the filing.
  • Vesting schedule: The RSUs vest in three equal yearly installments beginning on the first anniversary of the grant date of November 1, 2023.
  • Reporting person's role: Jane Grogan is identified in the filing as an officer with the title Head of Research at Biogen Inc. (NASDAQ:BIIB).
  • Filing signed by attorney-in-fact: The form was signed by Bryan Keighery as attorney-in-fact for Dr. Grogan, with a Power of Attorney attached as Exhibit 24.

Jane Grogan's October 2026 RSU Vesting and Share Withholding at Biogen

According to the Form 4 filed November 2, 2026, Jane Grogan, Biogen Inc.'s Head of Research, reported two transactions in Biogen common stock on October 30, 2026. The first was the conversion of 695 restricted stock units into common shares at $0 per unit, coded as an M transaction, bringing her directly held shares to 4,753 following that step.

The filing then reports a disposition of 345 shares at $253.62 per share under transaction code F, which the filing structure indicates represents shares withheld for tax purposes. After this disposition, Grogan's direct beneficial ownership stood at 4,408 shares of Biogen common stock, as reported in Table I of the filing.

Table II of the filing discloses that the derivative security involved was a restricted stock unit with a conversion price of $0, underlying 695 shares of common stock. The filing's footnote states that the restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of November 1, 2023, making October 30, 2026 consistent with the third and final installment of that grant. Following the reported transaction, zero restricted stock units of this grant remain outstanding, according to the filing.

What Was Disclosed

Biogen Inc. (NASDAQ:BIIB) officer Jane Grogan disclosed the vesting of 695 restricted stock units and the withholding of 345 resulting shares at $253.62 each on October 30, 2026, leaving her with direct ownership of 4,408 shares of common stock.